Articles Tagged With: treatment
-
Early Trial Results Suggest Many Acute Appendicitis Patients Could Safely Delay or Avoid Surgery
In a study, 70% of patients with appendicitis who were treated with antibiotics avoided surgery at 90 days. This creates possibilities for patients and providers for a common diagnosis in the ED.
-
IqYmune for CIDP
IqYmune is a highly purified 10% concentration of human immunoglobulin obtained from healthy volunteers. It appears to have similar efficacy in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as conventional intravenous immunoglobulin, with 76% of the study patients showing a significant improvement in a standardized disability score.
-
COVID-19 Infection in MS Patients
In a multicenter, retrospective analysis of patients in a multiple sclerosis (MS) registry, the authors described the clinical characteristics and risks associated with severity of complications from COVID-19 infection in patients with MS.
-
Scrambler Therapy for Neuromyelitis Optica Pain Treatment
Scrambler therapy appears to significantly reduce central neuropathic pain for patients with neuromyelitis optica spectrum disorder, although pain reduction is not shown to be sustained for more than 30 days after treatment.
-
Surgeon General Report Prioritizes Hypertension Control
Nation’s top doc calls on clinicians and patients to reverse negative trends.
-
Lessons Learned — or Not — from Hydroxychloroquine Mishap
The research community’s decades of work to build public trust in IRB oversight and the clinical trial process has reached one of its greatest challenges during the COVID-19 pandemic. Misinformation spread through social media and some media outlets, as well as contradictory instructions and information from political and public health officials, have helped create distrust. Through the spring of 2020, misinformation about hydroxychloroquine as a COVID-19 therapeutic proliferated after President Trump spoke about it as a cure.
-
Oral Calcitonin Gene-Related Peptide Antagonist for Prevention of Migraine
Atogepant, an oral calcitonin gene-related peptide (CGRP) antagonist, was shown to be effective and safe for migraine prevention. This adds an additional CGRP antagonist to the growing arsenal of such medications, both oral and parenteral, for both prevention and treatment of migraine.
-
Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder
Presenting with persistent inattentiveness and/or hyperactivity and impulsivity severe enough to interfere with functioning, and occurring in more than one setting, attention deficit hyperactivity disorder is one of the most common neurodevelopmental disorders of childhood, with evidence of impairment often continuing into adult years.
-
Vitamin C, Thiamine, and Steroids for Septic Shock — Still Unproven
Combination treatment with ascorbic acid (vitamin C), thiamine (vitamin B1), and corticosteroids does not improve clinical outcomes in adults with septic shock.
-
Four Months of Rifampin Is Just as Effective, Safer, and Less Expensive than Nine Months of Isoniazid for Latent Tuberculosis
A health system cost comparison found that four months of rifampin was safer and less expensive than nine months of isoniazid in high-income countries, medium-income countries, and African countries.